Acquired Company

Bristol Myers Squibb completed its acquisition of Mirati Therapeutics on January 23, 2024.

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops candidate products to address the genetic and immunological promoters of cancer in the United States. The company is headquartered in San Diego, California. Show more

3545 CRAY COURT, SAN DIEGO, CA, UNITED STATES, 92121, California, 92121-3070, USA

BIOTECHNOLOGY

HEALTHCARE

Market Cap

4.118B

52 Wk Range

$0.00 - $0.00

Previous Close

$58.70

Open

$58.70

Volume

N/A

Day Range

$58.70 - $58.70

Enterprise Value

0.00

Cash

258.7M

Avg Qtr Burn

-143.7M

Insider Ownership

1.72%

Institutional Own.

Qtr Updated

09/30/23

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Sitravatinib (TAM inhibitor) plus nivolumab (OPDIVO®) Details Non-small cell lung carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sitravatinib plus tislelizumab Details Platinum-resistant ovarian cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.